Three firms—AMA Medical Manufacturing Firm, Echitab Research Group Nigeria, and Micropharm Ltd., UK—signed a Memorandum of Understanding (MOU) on Tuesday to supply Anti-Snake Venom (ASV) medicine in Nigeria.
The Information Company of Nigeria (NAN) stories that the signing ceremony, held on the AMA Medical Manufacturing Firm in Kudenda, Kaduna, marks a major milestone within the nation’s efforts to domestically manufacture these important drugs.
Talking on the MOU signing ceremony, Prof. Nasidi Abdulsalami, Chairman of AMA Medical Manufacturing Firm, described the Contract as a major step ahead for the nation.
Abdulsalami emphasised that the MOU is a constructive instance of public-private partnership, and he expressed optimism in regards to the full participation of the federal and state governments, in addition to different Nigerians.
He mentioned, “We count on significant Nigerians which are blessed to contribute as a result of it’s a social funding geared toward saving lives. The ASV medicine are life saving merchandise. We will by no means enable the medicine to fade as a result of Nigerians want them, particularly the farmers and herders.”
“The MOU signing right this moment serves as the start of self-sufficiency for the product not solely within the nation, however your entire continent as a result of international locations look as much as Nigeria for good management.”
“I’m proud to announce that the World Well being Organisation has examined all of the ASV medicine out there on this planet and discovered that our ASV, for which we’re growing this partnership right this moment with micropharm, is the perfect. Micropharm merchandise which are produced within the UK are the perfect; the second is the one produced by Costa Rica.”
Prof. Nasidi Abdulsalami praised Dr. Nandul Durfa, the Managing Director of Echitab Research Group Nigeria, for his unwavering dedication to the aim of domestically producing Anti-Snake Venom (ASV) medicine in Nigeria.
Abdulsalami famous that the achievement marked a major milestone that needs to be celebrated, because it offered a long-awaited answer to a persistent drawback.
Mr. Lan Cameroon, Chief Government Officer of Micropharm, expressed his gratitude for the signing of the MOU and lamented the continuing shortage of ASV medicine within the nation. He recounted that the seek for ASV medicine in Nigeria started within the early Nineteen Seventies when Prof. David Wanns of ABU, Zaria, took a dwell snake from Nigeria to Liverpool, the place the primary venom was extracted for production. Cameroon additionally acknowledged that with native production, the price of ASV medicine would considerably lower, and the medicine would grow to be extra available.
Mr. Marc Nassar of Von hram remarked that the MoU would introduce new know-how into Nigeria, noting that his group, identified for its experience in managing know-how, was the primary to convey superior know-how to the prevailing AMA plant. He expressed optimism that the collaboration would harness this experience to attain success.
